Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves

  • Matteo Pagnesi
  • Won-Keun Kim
  • Sara Baggio
  • Andrea Scotti
  • Marco Barbanti
  • Federico De Marco
  • Marianna Adamo
  • Amnon Eitan
  • Rodrigo Estévez-Loureiro
  • Lenard Conradi
  • Stefan Toggweiler
  • Darren Mylotte
  • Verena Veulemans
  • Lars Søndergaard
  • Alexander Wolf
  • Francesco Giannini
  • Diego Maffeo
  • Thomas Pilgrim
  • Matteo Montorfano
  • David Zweiker
  • Marco Ferlini
  • Ran Kornowski
  • David Hildick-Smith
  • Maurizio Taramasso
  • Alexandre Abizaid
  • Joachim Schofer
  • Jan-Malte Sinning
  • Nicolas M Van Mieghem
  • Jochen Wöhrle
  • Saib Khogali
  • Jan A S Van der Heyden
  • David A Wood
  • Alfonso Ielasi
  • Philip MacCarthy
  • Salvatore Brugaletta
  • Christian W Hamm
  • Giuliano Costa
  • Luca Testa
  • Mauro Massussi
  • Robert Alarcón
  • Ulrich Schäfer
  • Stephanie Brunner
  • Bernhard Reimers
  • Mattia Lunardi
  • Tobias Zeus
  • Maarten Vanhaverbeke
  • Christoph K Naber
  • Luca Di Ienno
  • Andrea Buono
  • Stephan Windecker
  • Albrecht Schmidt
  • Giuseppe Lanzillo
  • Hana Vaknin-Assa
  • Sandeep Arunothayaraj
  • Matteo Saccocci
  • Dimytri Siqueira
  • Christina Brinkmann
  • Alexander Sedaghat
  • Francesca Ziviello
  • Julia Seeger
  • Wolfgang Rottbauer
  • Jorn Brouwer
  • Ian Buysschaert
  • Julius Jelisejevas
  • Apurva Bharucha
  • Ander Regueiro
  • Marco Metra
  • Antonio Colombo
  • Azeem Latib
  • Antonio Mangieri

Abstract

OBJECTIVES: The authors sought to evaluate the incidence, predictors, and outcomes of new permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) with contemporary self-expanding valves (SEV).

BACKGROUND: Need for PPI is frequent post-TAVR, but conflicting data exist on new-generation SEV and on the prognostic impact of PPI.

METHODS: This study included 3,211 patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries (January 2012 to December 2021) who underwent transfemoral TAVR with SEV. Implanted transcatheter heart valves (THV) were Acurate neo (n = 1,090), Acurate neo2 (n = 665), Evolut PRO (n = 1,312), and Evolut PRO+ (n = 144). Incidence and predictors of new PPI and 1-year outcomes were evaluated.

RESULTS: New PPI was needed in 362 patients (11.3%) within 30 days after TAVR (8.8%, 7.7%, 15.2%, and 10.4%, respectively, after Acurate neo, Acurate neo2, Evolut PRO, and Evolut PRO+). Independent predictors of new PPI were Society of Thoracic Surgeons Predicted Risk of Mortality score, baseline right bundle branch block and depth of THV implantation, both in patients treated with Acurate neo/neo2 and in those treated with Evolut PRO/PRO+. Predischarge reduction in ejection fraction (EF) was more frequent in patients requiring PPI (P = 0.014). New PPI was associated with higher 1-year mortality (16.9% vs 10.8%; adjusted HR: 1.66; 95% CI: 1.13-2.43; P = 0.010), particularly in patients with baseline EF <40% (P for interaction = 0.049).

CONCLUSIONS: New PPI was frequently needed after TAVR with SEV (11.3%) and was associated with higher 1-year mortality, particularly in patients with EF <40%. Baseline right bundle branch block and depth of THV implantation independently predicted the need of PPI.

Bibliografische Daten

OriginalspracheEnglisch
ISSN1936-8798
DOIs
StatusVeröffentlicht - 28.08.2023

Anmerkungen des Dekanats

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PubMed 37480891